Abstract
The field of immuno-oncology (IO) is rapidly expanding, generating enormous interest on the part of drug developers and giving new hope to patients and physicians. Attempts to harness the immune system to fight cancer date back to the 19th century; however, it is only in recent years that immunotherapies have entered mainstream oncology and have shown promise across a broad range of tumor types. New therapeutic combinations are emerging, with companies pairing two immunotherapies, an immunotherapy and a molecularly targeted therapy, or an immunotherapy plus traditional chemotherapy in order to more effectively fight cancer. Some immunotherapies are also pairing with companion diagnostics in order to maximize efficacy in patient populations. All of these developments come with their own unique challenges that drug developers will need to confront. This Perspective article reviews developments in the IO field and highlights key challenges in successfully commercializing an IO therapy.
Keywords: Commercialization, companion diagnostics, immuno-oncology, oncology, precision medicine.
Current Pharmacogenomics and Personalized Medicine
Title:IO Nation: The Rise of Immuno-Oncology
Volume: 12 Issue: 3
Author(s): Scott Palmer, Georgiana L. Kuhlmann and Kristin Pothier
Affiliation:
Keywords: Commercialization, companion diagnostics, immuno-oncology, oncology, precision medicine.
Abstract: The field of immuno-oncology (IO) is rapidly expanding, generating enormous interest on the part of drug developers and giving new hope to patients and physicians. Attempts to harness the immune system to fight cancer date back to the 19th century; however, it is only in recent years that immunotherapies have entered mainstream oncology and have shown promise across a broad range of tumor types. New therapeutic combinations are emerging, with companies pairing two immunotherapies, an immunotherapy and a molecularly targeted therapy, or an immunotherapy plus traditional chemotherapy in order to more effectively fight cancer. Some immunotherapies are also pairing with companion diagnostics in order to maximize efficacy in patient populations. All of these developments come with their own unique challenges that drug developers will need to confront. This Perspective article reviews developments in the IO field and highlights key challenges in successfully commercializing an IO therapy.
Export Options
About this article
Cite this article as:
Palmer Scott, Kuhlmann L. Georgiana and Pothier Kristin, IO Nation: The Rise of Immuno-Oncology, Current Pharmacogenomics and Personalized Medicine 2014; 12 (3) . https://dx.doi.org/10.2174/1875692113666150115222451
DOI https://dx.doi.org/10.2174/1875692113666150115222451 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biology of Mesenchymal Stem Cells
Current Rheumatology Reviews Ultrasound Promoted Green Synthesis, Docking Study of Indole Spliced Thiadiazole, α-amino Phosphonates as Anticancer Agents and Antityrosinase Agents
Anti-Cancer Agents in Medicinal Chemistry Chemoprevention Gene Therapy (CGT) of Pancreatic Cancer Using Perillyl Alcohol and a Novel Chimeric Serotype Cancer Terminator Virus
Current Molecular Medicine Functional PLGA NPs for Oral Drug Delivery: Recent Strategies and Developments
Mini-Reviews in Medicinal Chemistry Acid Ceramidase as a Chemotherapeutic Target to Overcome Resistance to the Antitumoral Effect of Choline Kinase α Inhibition
Current Cancer Drug Targets Graphical Abstracts
Letters in Drug Design & Discovery NSAIDs and Chemoprevention
Current Cancer Drug Targets Biological Activities and In Silico Physico-Chemical Properties of 1,2,3- Triazoles Derived from Natural Bioactive Alcohols
Anti-Infective Agents Disulfide Linkage: A Potent Strategy in Tumor-Targeting Drug Discovery
Current Medicinal Chemistry Long Non-coding RNA HOTAIR Promotes Parkinson's Disease Induced by MPTP Through up-regulating the Expression of LRRK2
Current Neurovascular Research Knocking Down Gene Expression with Dendritic Vectors
Mini-Reviews in Medicinal Chemistry Treatment of Leishmaniasis: A Review and Assessment of Recent Research
Current Pharmaceutical Design Namitecan: a Hydrophilic Camptothecin with a Promising Preclinical Profile
Current Medicinal Chemistry GEMSP: A New Therapeutic Approach to Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry Telomerase Modulation in Therapeutic Approach
Current Pharmaceutical Design Fused Xanthone Derivatives as Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry β-Hydroxy-β-Methylbutyrate as a Countermeasure for Cancer Cachexia: A Cellular and Molecular Rationale
Anti-Cancer Agents in Medicinal Chemistry HLA-G - From Fetal Tolerance to a Regulatory Molecule in Inflammatory Diseases
Current Immunology Reviews (Discontinued) Ferulic Acid Activity in Topical Formulations: Technological and Scientific Prospecting
Current Pharmaceutical Design Expression and Characterisation of Recombinant Molecules in Transgenic Soybean
Current Pharmaceutical Design